Anika Therapeutics | ANIK - Current Liabilities


Anika Therapeutics reported $20.97M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Agenus USD 249.24M 74.25M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Integra LifeSciences USD 346.85M 109.14M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Merit Medical Systems USD 216.87M 22.89M Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Smith & Nephew USD 1.54B 236M Dec/2025
Stryker USD 6.32B 1.48B Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026
Zimmer Biomet Holdings USD 2.86B 280.6M Mar/2026